BridgeBio reports BBO-8520 response data, cash runway into 2028
BridgeBio said BBO-8520 plus pembrolizumab showed a 75% ORR at 500 mg QD, 53% across doses, and monotherapy produced a 63% ORR. It also said cash runway was $344.1 million into 2028.
Key Highlights:Original SEC Filing: BridgeBio Oncology Therapeutics, Inc. [ BBOT ] - 8-K - Sep. 08, 2026This is an AI-po…